<DOC>
	<DOCNO>NCT00954135</DOCNO>
	<brief_summary>Endocrine therapy mainstay systemic treatment patient endocrine responsive breast cancer . Aromatase inhibitor active agent post-menopausal woman . Randomized comparison either primary/adjuvant setting metastatic disease set demonstrate superiority drug tamoxifen . Primary systemic treatment administer breast cancer patient useful model identify baseline feature able predict patient likely benefit cytotoxic treatment way study new biological marker relation predictive information provide . This treatment modality represent therefore best way explore new treatment strategy particular treatment strategy involve target therapy . We conduct randomised phase II trial activity Letrozole plus/minus oral metronomic cyclophosphamide primary systemic treatment investigate patient population elderly breast cancer patient . The conclusion combination letrozole metronomic cyclophosphamide active scheme . In addition first study demonstrate vivo antiangiogenic effect metronomic scheduling . This study suggest chemotherapy administer metronomic schedule , target therefore neo-angiogenesis , could synergistic endocrine therapy aromatase inhibitor . Sorafenib multi-kinase inhibitor target Raf , VEGFR-1 , VEGFR-2 , VEGFR-3 , PDGFR-alfa , Flt-3 , c-Kit , p38 . There strong rationale combine different anti-angiogenic agent . At ASCO 2007 meeting data phase I study explore toxicity combination sorafenib bevacizumab present . The result show increased toxicity dose limit patient . To knowledge data un activity toxicity add sorafenib metronomic chemotherapy .</brief_summary>
	<brief_title>Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib Primary Systemic Treatment Breast Cancer Patients</brief_title>
	<detailed_description>Primary Objective : To compare activity 2 regimens The primary end point clinical complete response rate treatment arm among registered case ( intent treat analysis ) . Secondary Objectives : To compare 2 treatment arm respect : - Toxicity - Progression Free Survival - Overall survival Ancillary study To evaluate treatment number marker hypoxia , neoangiogenesis , apoptosis , EGFR activate pathway .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Women postmenopausal status 2 . Age &gt; 60 age &gt; 18 unfit chemotherapy commonly employ regimen breast cancer patient 3 . Diagnosis invasive BC , T &gt; 2 , N0N2 , M0 , 4 . Endocrine Responsive disease accord San Gallen criterion 5 . ECOG Performance Status 0 2 6 . Life expectancy least 12 week 7 . In case recent surgery , wound must completely heal prior receive Sorafenib 8 . Subjects least one unidimensional ( RECIST ) bidimensional ( WHO ) measurable lesion . Lesions must measure CTscan MRI 9 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : 10 . Hemoglobin &gt; 9.0 g/dl 11 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 12 . Platelet count 100,000/Î¼l 13 . Total bilirubin &lt; 1.5 time upper limit normal 14 . ALT AST &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) 15 . Alkaline phosphatase &lt; 4 x ULN 16 . PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] 17 . Serum creatinine &lt; 1.5 x upper limit normal . 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrythmias require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 2 . History HIV infection chronic hepatitis B C ( This criterion modify allow Hepatitis B C protocols look HCC patient population ) . 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 4 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) 5 . Patients seizure disorder require medication ( steroids antiepileptic ) 6 . History organ allograft The organ allograft may allow protocol specific . 7 . Patients evidence history bleed diathesis 8 . Patients undergoing renal dialysis 9 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>neoadjuvant therapy , sorafenib , letrozolo , cyclophosphamide</keyword>
</DOC>